CYP19A1 and breast carcinoma: The compounds were evaluated in vitro for their ability to inhibit aromatase and bind to estrogen receptor α (ER-α) and estrogen receptor β (ER-β) and antagonize the effects of β-estradiol in MCF-7 human breast cancer cells.